Stem Cell Treatment for Cardiovascular in Delhi, India

What causes cardiovascular disease?

CVD develops through a combination of modifiable and non-modifiable risk factors. Distinguishing between them matters because it affects both prevention and — for candidacy purposes — how your cardiologist frames your case:

• High blood pressure (hypertension) — sustained strain on the heart and arterial walls, accelerating damage over time.
• High cholesterol (dyslipidemia) — cholesterol buildup narrows arteries, restricting blood flow and increasing heart attack and stroke risk.
• Diabetes — elevated blood sugar damages blood vessels and accelerates atherosclerosis; see our Diabetes treatment page if this is a contributing factor in your case.
• Smoking and tobacco use — damages arterial walls directly and raises heart rate and blood pressure.
• Obesity — compounds risk both directly and through its links to hypertension and diabetes.
• Family history / genetic predisposition — some cardiovascular conditions run in families independent of lifestyle factors.

Why this distinction matters for a stem cell evaluation

Stem cell research in cardiology has concentrated on ischemic damage — tissue injury from reduced blood flow, most often following a heart attack — and on heart failure with reduced ejection fraction. It has not shown relevant application to valve disease, congenital defects, or arrhythmias caused by electrical conduction issues; these require cardiology-specific management (medication, ablation, or surgical correction) rather than a regenerative approach. If your diagnosis falls into one of these categories, our specialist team will tell you directly that stem cell therapy isn’t the right next step, rather than proposing an unsuitable protocol.

Related reading: How Stem Cell Therapy Works for the general mechanism, or jump to Diagnosis to see the tests used to confirm which category applies to your case.

What are the symptoms of cardiovascular disease?

Symptoms vary by the specific condition, but the most common warning signs include:

• Chest pain or discomfort (angina) — often described as pressure, tightness, or squeezing, sometimes radiating to the arm, jaw, or back.
• Shortness of breath — during exertion or, in more advanced cases, at rest.
• Fatigue and reduced stamina — noticeably lower tolerance for activities that were previously manageable.
• Heart palpitations or irregular heartbeat — a sensation of skipped beats, fluttering, or racing.
• Swelling in the legs, ankles, or feet (oedema) — a common sign of heart failure as fluid backs up in the circulatory system.
• Dizziness or fainting — can indicate reduced blood flow to the brain from cardiac causes.
• Difficulty sleeping flat / waking breathless at night — a specific heart-failure symptom worth mentioning to your doctor by name.

When these symptoms warrant urgent care, not a stem cell consultation

Sudden, severe chest pain, breathlessness, or fainting are medical emergencies. Seek immediate emergency care rather than researching treatment options online. Stem cell therapy is only ever considered after a patient is medically stable and has completed a full cardiac diagnostic work-up — see Diagnosis below.

How is cardiovascular disease diagnosed?

No stem cell protocol is proposed at Viezec without a completed cardiology work-up, reviewed alongside your treating cardiologist’s findings. This typically includes:

Alongside testing, your cardiologist will review lifestyle and risk factors — family history, diet, activity levels, tobacco/alcohol use, and existing conditions like diabetes or hypertension — since these affect both your baseline risk and your suitability for any regenerative approach.

If you already have recent cardiology reports (within the last 3–6 months), you can upload them for a free specialist review rather than repeating tests unnecessarily.

Note on interpreting your own results: A reduced ejection fraction or confirmed ischemic damage doesn’t automatically make you a stem cell candidate — overall cardiac stability, other organ function, and your cardiologist’s assessment of your standard treatment response are all read together. This is explained further under Who Is a Candidate in the Treatment section below.

Stem Cell Treatment for Cardiovascular Disease in India

Stem cell therapy for cardiovascular disease uses mesenchymal or donor-derived stem cells, under investigation for their potential to support angiogenesis (new blood vessel formation) and cardiac tissue repair in patients with ischemic heart disease, post-heart-attack damage, or heart failure. It is delivered by our specialist team at Viezec’s accredited New Delhi facility as a supportive, investigational addition to standard cardiology care — not a replacement for it. Eligibility depends entirely on your specific cardiac diagnosis, confirmed beforehand — see Diagnosis.

How does it work?

Stem cells are being researched for several mechanisms relevant to cardiac repair (see Mechanism below for more detail):

• Supporting angiogenesis — encouraging new blood vessel growth around blocked or narrowed coronary arteries, which may help restore blood flow to oxygen-starved heart tissue.
• Cardiomyocyte support — paracrine (cell-signalling) effects that may help protect or support surviving heart muscle cells near an area of damage.
• Reducing post-MI scar burden — early research is exploring whether stem cell delivery shortly after a heart attack can influence how much of the heart muscle is replaced by non-functional scar tissue versus preserved.

Cells are collected either from the patient herself (autologous) or from screened donor sources including cord blood (allogeneic), processed under laboratory conditions, and delivered via the methods described in Implantation below.

Who is a candidate?

You may be considered a candidate if you have a confirmed diagnosis of:

• Ischemic heart disease with documented reduced blood flow
• Heart failure with reduced ejection fraction
• Cardiac damage following a confirmed heart attack (post-MI)
• Cardiomyopathy where standard treatment has plateaued

You are not likely to be a candidate if your condition is primarily valvular (requiring surgical or catheter-based valve repair), a congenital structural defect, or an arrhythmia driven by electrical conduction abnormalities — these need cardiology-specific management rather than a regenerative approach.

What to expect: the treatment process

1. Consultation and cardiology review — your existing reports (ECG, echocardiogram, angiography, cardiac MRI) are reviewed by our specialist team alongside your treating cardiologist’s input.
2. Cell sourcing — bone marrow or adipose tissue collection under local anaesthesia (autologous), or use of screened donor/cord-blood sources (allogeneic).
3. Lab processing — cells are isolated and prepared under controlled laboratory conditions, with certification detailed under Quality Certificate.
4. Administration — via the delivery method appropriate to your case; see Implantation.
5. Follow-up monitoring — cardiac function tracking (echocardiogram, symptom review) over the following weeks and months.

For international patients, see our visa and travel support and plan-your-visit resources.

Stem Cell Delivery Methods for Cardiovascular Disease

The delivery method used for cardiovascular stem cell therapy depends on your specific diagnosis, the treatment protocol selected by your specialist, and practical factors like accessibility of the affected tissue. Methods evaluated in current practice include:

1. Intravenous (IV) administration — cells delivered through a peripheral vein, allowing systemic circulation.
2. Intramuscular injection — direct delivery into muscle tissue in select protocols.
3. Subcutaneous administration — delivery beneath the skin, used in specific supportive protocols.
4. Catheter-based (angioplasty-guided) delivery — cells delivered directly to the coronary arteries or cardiac tissue via a minimally invasive catheter, guided by imaging.
5. Intrathecal administration — relevant primarily where a combined neuro-cardiac protocol is used, not standard for isolated cardiac cases.
6. Surgical administration — used in select complex cases requiring direct surgical access.

Your treating specialist selects the delivery method based on your diagnosis, overall cardiac stability, and the specific area of the heart requiring support — this decision is made only after your full diagnostic review, not before.

Read our full breakdown of Stem Cell Delivery Methods for how each approach is selected across different conditions.

Improvements Reported After Stem Cell Therapy for Cardiovascular Disease

Patients undergoing investigational stem cell therapy for cardiovascular disease at Viezec have reported changes in specific symptom and function markers — though, consistent with the evidence status described throughout this page, individual results vary and are not guaranteed.

What’s typically monitored

What has been reported by some patients

Reported improvements in some patients include reduced shortness of breath, lower medication burden, reduced fatigue, and less swelling (oedema). These are treated as clinical observations to be reviewed with your cardiologist, not as guaranteed or average outcomes — individual response depends on the extent of existing cardiac damage, age, and overall health.

Safety monitoring: Because stem cell delivery — whether IV or catheter-based — is an active medical procedure, patients are monitored closely post-treatment. Mild, expected reactions such as low-grade fever following IV or catheter-based delivery are consistent with typical post-injection response and are distinguished from serious adverse events during follow-up.

Mechanism of Action in Cardiovascular Disease

Stem cells are being researched as a way to support the heart’s own repair capacity rather than to “regrow” a heart directly. Once introduced into the body following processing and testing, cells are studied for their potential to influence the cardiac tissue environment in several ways:

• Differentiation-adjacent support — some research explores whether stem cells contribute cells with cardiac-muscle-like properties near damaged tissue, though the extent of true functional differentiation remains an active research question.
• Angiogenesis — supporting the formation of new blood vessels around blocked or narrowed coronary arteries, potentially improving blood flow to previously oxygen-starved tissue — relevant to conditions like ischemic heart disease and angina.
• Paracrine signalling — stem cells release signalling factors that may support the survival and function of nearby heart muscle cells, independent of directly becoming heart tissue themselves.
• Reducing local inflammation — potentially limiting the extent of inflammatory damage in the period following a heart attack.

This is described in more technical depth in our general explainer: Physiological Mechanism of Stem Cell Therapy.

Our Promise

Viezec is committed to transparent, evidence-based regenerative medicine care for cardiovascular patients — not overstated promises. In practice, this means:

• No cure claims. Stem cell therapy is offered as a researched, investigational, complementary option — never marketed as a guaranteed cure for cardiovascular disease.
• Cardiology work-up before treatment. No stem cell protocol is proposed without a completed ECG, echocardiogram, and relevant imaging confirming candidacy, reviewed alongside your treating cardiologist.
• Named, credentialed medical oversight. Every treatment plan is reviewed by a qualified regenerative medicine specialist.
• Regulatory transparency. Our protocols operate within India’s regulatory framework for investigational stem cell use, and we disclose which framework applies to your specific treatment when asked, directly and in writing.
• Accredited facilities. Our treatment and cell-processing facilities hold NABH accreditation and NABL accreditation , verifiable through each body’s public registry.
• Written, itemized cost estimates. No flat public pricing, because cost genuinely varies by diagnosis and protocol — but a clear, written estimate is provided after your cardiology evaluation, before you commit to anything.
• Location and access clarity. Our facility is based in New Delhi, India, with dedicated international patient support including visa assistance, accommodation coordination, and structured follow-up monitoring.
• Honest evidence communication. Where clinical evidence is still developing — as it is for stem cell therapy in cardiovascular disease — we say so directly and cite the specific studies our approach is based on, rather than implying stronger proof than currently exists. See Scientific References.

Treatment Results of Cardiovascular Disease

Investigational stem cell therapy for cardiovascular disease at Viezec (Delhi, India) is used to support cardiac tissue function in specific cases — primarily ischemic heart disease and post-heart-attack damage — through mechanisms including angiogenesis support and paracrine signalling. It is not a guaranteed cure and outcomes vary by diagnosis, cardiac damage extent, age, and overall health, evaluated case-by-case by our specialist team.

What does current research show?

• A 2025 comprehensive review of clinical trial progress (Regenerative Therapy, ScienceDirect) examines the state of stem cell therapies specifically for advanced heart failure, tracking trial progress across cell types and delivery methods.
• A 2025 review of research progress (Frontiers in Cell and Developmental Biology) covers stem cell applications in atherosclerosis, the underlying process behind most ischemic heart disease.
• A 2025 comparison study from Nottingham University Hospital (NHS, UK), published in Cureus, compares stem cell therapy outcomes against conventional heart disease treatment approaches.
• A 2022 position review from the University of Dhaka outlines both the opportunities and the unresolved challenges in cardiovascular stem cell therapy as of its publication.
• A 2024 review assesses the potential benefits of stem cell therapy specifically for cardiac regeneration in ischemic heart disease patients.
• A cross-sectional survey of registered clinical trials (Yang R, Zhang Y, et al., Frontiers in Cardiovascular Medicine, 2021) catalogues the scope and design of stem cell heart disease trials registered on ClinicalTrials.gov — useful context for understanding how much of this field remains in active trial stages rather than standardized practice.
• A registered Phase III randomized clinical trial (Attar A et al.) is evaluating mesenchymal stem cell transplantation specifically for preventing heart failure following acute myocardial infarction — one of the more advanced-stage trials in this area.

What results can realistically be expected?

Who is this typically considered for?

• Patients with confirmed ischemic heart disease and documented reduced blood flow
• Patients with heart failure and reduced ejection fraction, where standard treatment has plateaued
• Patients with confirmed post-heart-attack (post-MI) cardiac damage

Not typically indicated for valve disease, congenital structural defects, or conduction-related arrhythmias — these require cardiology-specific management.

Is this a replacement for conventional heart treatment?

No. Stem cell therapy at Viezec is offered as a complementary, physician-supervised option alongside — not instead of — standard cardiology care, medication, and any surgical or catheter-based intervention your cardiologist has recommended.

Testimonials

Manish R. – Pune, India – February 2020 – ⭐⭐⭐⭐☆
“I had chronic chest pain due to blocked arteries. After Viezec’s stem cell therapy, my stamina improved, and I walk daily without discomfort.”

Claire M. – Paris, France – July 2020 – ⭐⭐⭐⭐⭐
“My father’s heart failure was progressing. Post-treatment at Viezec, his energy levels returned, and he manages daily life better.”

Yusuf H. – Muscat, Oman – October 2020 – ⭐⭐⭐⭐☆
“I was diagnosed with poor heart function. Stem cell therapy at Viezec stabilized my condition and reduced breathlessness.”

Laura G. – Toronto, Canada – March 2021 – ⭐⭐⭐⭐⭐
“After a mild heart attack, recovery was slow. Thanks to Viezec’s therapy, my heart function improved, and I feel stronger now.”

Carlos V. – São Paulo, Brazil – September 2021 – ⭐⭐⭐⭐☆
“Climbing stairs was impossible before. After Viezec’s stem cell therapy, my shortness of breath decreased, and I’m more active.”

Fatima A. – Casablanca, Morocco – February 2022 – ⭐⭐⭐⭐⭐
“Heart disease left me weak for years. After treatment at Viezec, my heart health improved, and I live with more confidence.”

Peter N. – Berlin, Germany – August 2022 – ⭐⭐⭐⭐☆
“Doctors warned me about worsening heart failure. Viezec’s stem cell therapy gave me stability, and I no longer feel constant fatigue.”

Hana S. – Nairobi, Kenya – April 2023 – ⭐⭐⭐⭐⭐
“My husband’s cardiovascular condition was severe. Post-treatment, his circulation improved, and he regained strength.”

Ivan K. – Sofia, Bulgaria – November 2023 – ⭐⭐⭐⭐☆
“I lived with irregular heartbeats. After stem cell therapy at Viezec, my rhythm stabilized, and I feel much safer now.”

Sarah J. – Sydney, Australia – June 2025 – ⭐⭐⭐⭐⭐
“My cardiovascular health was declining fast. Thanks to Viezec’s therapy, I have better heart function and a renewed lifestyle.”

Ahead of undergoing this process; a patient needs to understands that stem cell therapy is an experimental therapy that might not work at certain times. At the time of procedure, a patient might be refused the treatment or the proposed protocol might change depending on the patient’s health condition.

At Viezec Stem Cell Institute, our main motive is to give the best technology and safety available; of which has been proven across the globe.

As with any medical treatment, there are no guarantees or claims of cures are made as to the extent of the response to treatment. Every patient has different internal status of body; hence results vary from patient to patient, even with a similar diagnosis. This means that we cannot offer, infer or suggest that there is any certainty of a given outcome. For our any treatment we do not use embryonic or fetal cells.